{"entity":{"id":"nct06271837","kind":"trial","name":"A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors","aka":["DESTINY PanTumor03"],"tldr":"A phase 2 trial of Trastuzumab deruxtecan and Bevacizumab in gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting.","summary":"A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors is a phase 2 interventional study registered as NCT06271837 by AstraZeneca, with 127 participants enrolled, started 2024-02-22 and due to reach its primary completion in 2027-02-10. Interventions recorded: Trastuzumab deruxtecan and Bevacizumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06271837","url":"https://clinicaltrials.gov/study/NCT06271837"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric","gastric-her2-positive"],"sections":[],"technologies":["adc","topoisomerase-inhibitors"],"targets":[],"drugs":["trastuzumab-deruxtecan","bevacizumab"],"companies":["astrazeneca","daiichi-sankyo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06271837","phase":"2","setting":"A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) as Monotherapy or in Combination With Anti-cancer Agents for the Treatment of Patients With Selected HER2-expressing Tumors (DESTINY PanTumor03)","sponsor":"AstraZeneca","participation":[{"nct":"NCT06271837","source":"https://clinicaltrials.gov/study/NCT06271837","fetchedAt":"2026-10-07T16:54:29.928Z","studySha256":"f09cd63c22515fa9f30716c9eda836566d085313c68ddaaf84671524d66f8303","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-09-03","leadSponsor":"AstraZeneca","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"130 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":127,"enrolmentType":"ACTUAL","siteCount":29,"recruitingSiteCount":0,"countries":["China"]}],"started":"2024-02-22","startedType":"actual","enrolled":127,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06271837/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"gastric-her2-positive","kind":"cancer","name":"HER2-positive gastric cancer","route":"/cancers/gastric-her2-positive/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"}]}}